Affordable Access

Publisher Website

Weekly high-dose infusion of 5-fluorouracil in advanced colorectal cancer

Authors
Journal
European Journal of Cancer and Clinical Oncology
0277-5379
Publisher
Elsevier
Publication Date
Volume
26
Issue
6
Identifiers
DOI: 10.1016/0277-5379(90)90128-g
Disciplines
  • Medicine

Abstract

Abstract 18 patients with advanced colorectal cancer entered a phase I–II study of high-dose 48 h continuous infusion 5-fluorouracil (5-FU) for 6 weeks. 7 patients were included at the first dose level (3 g/m 2) and only 1 had serious toxicity (grade 3 diarrhoea and mucositis). 7 patients were included at the second dose level (3.5 g/m 2). 6 had a good tolerance to treatment, while the remaining patient had grade 4 leukopenia. 4 patients received 4 g/m 2: 3 had severe toxicity (grade 4 diarrhoea, myelosuppression, mucositis, central nervous system), such that the entry of new patients was stopped. Anti-tumour activity was seen in 33% (95% confidence interval 13–59%) of the overall population. Only patients who had not had previous chemotherapy responded to treatment (response rate in this subgroup [43%, 18–71%]). The optimal dose of 5-FU was 3.5 g/m 2 weekly for six cycles.

There are no comments yet on this publication. Be the first to share your thoughts.